Vyepti

Vyepti is indicated for prophylaxis of migraine in adults.

The recommended dose is 100 mg administered by intravenous infusion every 12 weeks. Some patients may benefit from a dosage of 300 mg administered by intravenous infusion every 12 weeks.
Elderly patients (>65 years): Although patients up to 75 years of age were included in one study, the Vyepti clinical study program did not include numbers of patients aged ≥65 to determine whether they responded differently than younger patients. Pharmacokinetics of Vyepti is not affected by age.
Use in Pediatrics: Safety and efficacy of eptinezumab in pediatric patients under 18 yr has not been established.
Route of Administration: Eptinezumab is for intravenous use only after dilution.

There is no overdosage experience with Vyepti. Doses up to 1000 mg have been administered intravenously to humans without tolerability issues or clinically significant adverse reactions. In the event of an overdose, the patient should be treated symptomatically, and supportive measures instituted as required.

Hypersensitivity to the active substance or any excipients of this drug.

Traceability: In order to improve the traceability of biological medicinal products, the name and the batch number of the administered medicinal product should be clearly recorded.
Serious hypersensitivity: Serious hypersensitivity reactions, including anaphylaxis reactions has been reported and may develop within minutes of the infusion. Serious hypersensitivity reactions may occur. If a serious hypersensitivity reaction occurs, administration of Vyepti should be discontinued immediately and appropriate therapy initiated.
Use in Pregnancy: Limited data. Vyepti should not be used by pregnant women, unless the potential benefit justifies the potential risk to the foetus.
Use in Lactation: No data is available. The developmental and health benefits of breastfeeding should be considered, as well as the mother's clinical need for Vyepti and any potential effects on the breastfed infant.

Pregnancy: Limited data. Vyepti should not be used by pregnant women, unless the potential benefit justifies the potential risk to the foetus.
Lactation: No data is available. The developmental and health benefits of breastfeeding should be considered, as well as the mother's clinical need for Vyepti and any potential effects on the breastfed infant.

Common: Nasopharyngitis and hypersensitivity reactions.
Rare: Anaphylaxis reactions.

Eptinezumab is not metabolized by cytochrome P450 enzymes. Therefore, interactions by eptinezumab with concomitant medications that are substrates, inducers, or inhibitors of cytochrome P450 enzymes are considered unlikely.

Antimigraine Preparations

N02CD05 - eptinezumab ; Belongs to the class of calcitonin gene-related peptide (CGRP) antagonists preparations. Used to relieve migraine.

K